| Name | Title | Contact Details |
|---|
Evergreen Medical Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Evergreen, AL. To find more information about Evergreen Medical Center, please visit www.evergreenmedical.org
Renue Physical Therapy was established in the Fall of 2011 with one clinic on Bay Road in Saginaw. Our goal from the start was to create a fully patient-focused practice model. We take pride in offering one-on-one treatment with the same therapy team throughout the course of therapy, providing a customized plan that is specific to your needs to help you achieve the best possible outcomes. Since our start in 2011, Renue has grown to more than 12 clinics serving the Great Lakes Bay Region and beyond, with locations in Auburn, Au Gres, Bay City, Bridgeport, Caro, Freeland, Midland, Saginaw and Shields.
AndHealth is a digital health solution that combines behavioral and clinical care for migraine and autoimmune conditions. Their virtual Center of Excellence delivers a Migraine Reversal Program via mobile app to enable migraine reversal.
Dayspring Services of Arkansas is a Springdale, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.